Thanks to the emergence of paradigm-shifting all-oral antiviral regimens, the hepatitis C virus (HCV) space has surged to become one of the sector’s most lucrative markets. Read More

Tracon Pharmaceuticals Inc., of San Diego, presented preclinical data from two separate liver fibrosis models in a poster, “Endoglin Antibody Reduces the NAFLD Activity Score in the STAM Model of NASH and Reduces Liver Fibrosis Following Carbon Tetrachloride Treatment.” Read More

Prometic Life Sciences Inc., of Laval, Quebec, presented new results from preclinical studies of PBI-4050 in cardiac and lung fibrosis, respiratory function, and lung structural remodeling following a myocardial infarction (MI) induced by coronary artery ligation. Beginning two weeks after the MI, the animals were treated with PBI-4050 for three weeks. Read More

Merck KGaA, of Darmstadt, Germany, announced results of the ADDRESS II phase IIb, multicenter study on atacicept in patients with systemic lupus erythematosus (SLE). Patients on standard-of-care therapy (n=306) were randomized to weekly subcutaneous injections of atacicept (75 or 150 mg) or placebo for 24 weeks. Read More